GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embla Medical hf (OTCPK:OSSUY) » Definitions » Debt-to-EBITDA
中文

Embla Medical hf (Embla Medical hf) Debt-to-EBITDA : 4.57 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Embla Medical hf Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Embla Medical hf's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $84.2 Mil. Embla Medical hf's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $475.6 Mil. Embla Medical hf's annualized EBITDA for the quarter that ended in Mar. 2024 was $122.4 Mil. Embla Medical hf's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 4.57.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Embla Medical hf's Debt-to-EBITDA or its related term are showing as below:

OSSUY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.92   Med: 2.18   Max: 5.55
Current: 3.22

During the past 13 years, the highest Debt-to-EBITDA Ratio of Embla Medical hf was 5.55. The lowest was 0.92. And the median was 2.18.

OSSUY's Debt-to-EBITDA is ranked worse than
75.12% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs OSSUY: 3.22

Embla Medical hf Debt-to-EBITDA Historical Data

The historical data trend for Embla Medical hf's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embla Medical hf Debt-to-EBITDA Chart

Embla Medical hf Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.53 5.55 3.03 4.12 3.25

Embla Medical hf Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.06 3.03 3.29 2.98 4.57

Competitive Comparison of Embla Medical hf's Debt-to-EBITDA

For the Medical Devices subindustry, Embla Medical hf's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embla Medical hf's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Embla Medical hf's Debt-to-EBITDA falls into.



Embla Medical hf Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Embla Medical hf's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(43.325 + 424.407) / 143.886
=3.25

Embla Medical hf's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(84.175 + 475.58) / 122.404
=4.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Embla Medical hf  (OTCPK:OSSUY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Embla Medical hf Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Embla Medical hf's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Embla Medical hf (Embla Medical hf) Business Description

Traded in Other Exchanges
Address
Grjothals 5, Reykjavik, ISL
Ossur hf is engaged in the design, development, manufacture, and sale of prosthetics and bracing & support products. The company's products improve mobility through technologies in the field of braces, supports, prosthetic limbs, and compression therapy. Its segments are the Bracing & Supports and Prosthetics segment. The bracing & support products are used to support joints and other body parts for therapeutic and preventative purposes. The Prosthetics segment includes artificial limbs and related products for individuals born without limbs. Its geographical segments are the Americas; Europe, the Middle East & Africa (EMEA); and the Americas & Asia-Pacific (APAC), of which the Americas generate nearly half of the company's revenue.